Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Search results

Found 14892 matches for

A new statement has been released from Professor Peter Horby and Professor Martin Landray, Chief Investigators of the RECOVERY Trial. RECOVERY was established in March as a randomised clinical trial to test a range of potential drugs for COVID-19, including hydroxycholoroquine. The trial has proceeded at unprecedented speed, enrolling over 11,000 patients from 175 NHS hospitals in the UK. The chief investigators have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with COVID-19.

Pills
Thomas Peto

Thomas Peto

Research Scientists

Gail Carson

Gail Carson

MSc IHTM Lecturers MSc IHTM steering committee Principal Investigators Research Scientists

Mehul Dhorda

Mehul Dhorda

Research Scientists

David Warrell

David Warrell

MSc IHTM Lecturers Principal Investigators Research Scientists

Wirichada Pan-ngum

Wirichada Pan-ngum

MSc IHTM Lecturers MSc MGH Lecturers Research Scientists

Eduard Sanders

Eduard Sanders

Principal Investigators Research Scientists

Anthony Scott

Anthony Scott

Principal Investigators Research Scientists

Ipsita Sinha

Ipsita Sinha

Research Scientists

Bridget Wills

Bridget Wills

MSc IHTM Lecturers Principal Investigators Research Scientists

Mathupanee Oonsivilai

MSc MGH Lecturers Research Scientists

Joel Tarning

Joel Tarning

MSc MGH Lecturers Principal Investigators Research Scientists

Mayfong Mayxay

Mayfong Mayxay

Research Scientists

Matthew Robinson

Matthew Robinson

Research Scientists

Juan Carrique-Mas

Juan Carrique-Mas

Principal Investigators Research Scientists

Guy Thwaites

Guy Thwaites

MSc IHTM steering committee Principal Investigators Research Scientists

Stuart Blacksell

Stuart Blacksell

Principal Investigators Research Scientists

Peter Horby

Peter Horby

MSc IHTM Lecturers MSc IHTM steering committee Principal Investigators Research Scientists

Sreymom Pol

Sreymom Pol

Research Scientists

Ben Cooper

Ben Cooper

MSc MGH Lecturers Principal Investigators Research Scientists

George Warimwe

George Warimwe

MSc IHTM Lecturers Principal Investigators Research Scientists

Load More

Similar stories

We gathered rich insights into child survival in Kenya by mapping patterns over 22 years

KWTRP Research

Although improvements in child survival globally have been remarkable, 5.2 million children still died in 2019, over half of these in sub-Saharan Africa. A range of factors likely include disparities in childhood immunisations, supplements and breastfeeding practices, antenatal care, skilled birth attendants working in healthcare facilities. Kenya needs to prioritise its child care plans, based on localities and populations with the greatest need. Two KWTRP studies give granular insights into the situation in regions across Kenya.

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.